+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Market Spotlight: Venous Thromboembolism (VTE)

  • Report

  • 36 Pages
  • February 2021
  • Region: Global
  • Citeline
  • ID: 5118950
This Market Spotlight report covers the Venous Thromboembolism market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The publisher estimates that in 2018, there were approximately 2.3 million incident cases of deep vein thrombosis (DVT) and 1.2 million incident cases of pulmonary embolism (PE) worldwide, and forecasts that these numbers will increase to 2.6 million incident cases of DVT and 1.3 million incident cases of PE by 2027.
  • Approved drugs in the venous thromboembolism (VTE) space focus on a wide variety of targets. These drugs are commonly administered via the subcutaneous route, with some products being available in oral and intravenous formulations.
  • The majority of industry-sponsored drugs in active clinical development for VTE are in Phase II. Therapies in active clinical development for VTE focus on a wide variety of targets. The majority of the pipeline drugs are administered via the intravenous route, with the remainder being oral and subcutaneous formulations.
  • The only high-impact upcoming event in the VTE space is an expected supplemental CHMP opinion for Xarelto. The overall likelihood of approval of a Phase I VTE asset is 20.2%, and the average probability a drug advances from Phase III is 70%. Drugs, on average, take 10.9 years from Phase I to approval, compared to 9.3 years in the overall hematology space.
  • The distribution of clinical trials across Phase I–IV indicates that the majority of trials for VTE have been in the late phases of development, with 72% of trials in Phase III–IV, and 28% in Phase I–II.
  • The US has a slight lead in the number of VTE clinical trials globally, while Germany leads the major European markets. Clinical trial activity in the VTE space is dominated by completed trials. Bayer has the highest number of completed clinical trials for VTE, with 38 trials.
  • Bayer leads the industry sponsors with the highest overall number of clinical trials for VTE.

Table of Contents

  • Disease definition
  • Symptoms
  • Risk factors
  • Diagnosis
  • Patient segmentation

  • Anticoagulants
  • Thrombolytic therapy
  • Inferior vena cava filter
  • Thrombectomy/embolectomy

  • Japan: Bayer’s Xarelto Receives Approval For Additional Indications Of Venous Thromboembolism
  • Accord Gets First EU-Wide Nod For Xarelto Rival

  • Sponsors by status
  • Sponsors by phase

  • Prescription information

Figure 1: Trends in incident cases of DVT, 2018–27
Figure 2: Trends in incident cases of PE, 2018–27
Figure 3: Overview of pipeline drugs for VTE in the US
Figure 4: Pipeline drugs for VTE, by company
Figure 5: Pipeline drugs for VTE, by drug type
Figure 6: Pipeline drugs for VTE, by classification
Figure 7: Probability of success in the VTE pipeline
Figure 8: Clinical trials in VTE
Figure 9: Top 10 drugs for clinical trials in VTE
Figure 10: Top 10 companies for clinical trials in VTE
Figure 11: Trial locations in VTE
Figure 12: VTE trials status
Figure 13: VTE trials sponsors, by phase
Table 1: Incident cases of DVT, 2018–27
Table 2: Incident cases of PE, 2018–27
Table 3: Marketed drugs for VTE
Table 4: Pipeline drugs for VTE in the US
Table 5: Historical global sales, by drug ($m), 2015–19
Table 6: Forecasted global sales, by drug ($m), 2021–25